From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the ...

Patrizia Busatto, MD, graduated with a degree in medicine from the University of Trieste, in Italy, where she specialized in ophthalmology. She is a member of the Italian Society of Ophthalmology and ...

Murthy Chavali is Director of Clinical Development at Ocugen, Inc. He is an accomplished leader in drug discovery, research and development with over 20 years of experience in academic and ...

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes. Now is an exciting time to be a ...

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Dr. Melissa Yuan discusses the impact of weight and postmenstrual age on foveal maturation in preterm infants, highlighting critical insights for neonatal care.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025. To strengthen Opus Genetics’ gene therapy program ...

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended. Christina Y. Weng, MD, MBA, and colleagues compared the intended ...